Menopausal Disorders Therapeutics
1. Osphena patent expiration
Treatment: Treatment of dyspareunia associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment...
OSPHENA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566252 | DUCHESNAY | Method for the alleviation of dyspareunia in women |
Nov, 2022
(3 years ago) | |
| US8470890 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US6245819 | DUCHESNAY | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Jul, 2025
(5 months ago) | |
| US9855224 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US9241915 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US8772353 | DUCHESNAY | Method for enhancing the bioavalability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US8236861 | DUCHESNAY | Method for enhancing the bioavailablity of ospemifene |
Aug, 2026
(6 months from now) | |
| US8642079 | DUCHESNAY | Solid formulations of ospemifene |
Jul, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
| New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Dosage: TABLET
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
2. Veozah patent expiration
Treatment: Treatment of moderate to severe vasomotor symptoms due to menopause
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9422299 | ASTELLAS | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(8 years from now) | |
| US8871761 | ASTELLAS | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10836768 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(8 years from now) | |
| US9987274 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2028 |
Drugs and Companies using FEZOLINETANT ingredient
NCE-1 date: 13 May, 2027
Market Authorisation Date: 12 May, 2023
Dosage: TABLET
More Information on Dosage
VEOZAH family patents